OKYO PHARMA LTD Stock Price, News & Analysis

OKYO Pharma (NASDAQ: OKYO) has been granted U.S. Patent No. 12,053,501 for its OK-101 drug, covering methods for treating symptoms of dry eye disease (DED). The patent, issued on August 6th, specifically addresses the use of OK-101 to treat irritated, burning eyes and blurred vision in DED patients. This development strengthens OKYO's intellectual property position in the multi-billion-dollar DED market.

OKYO Pharma is a clinical-stage biopharmaceutical company focusing on innovative ocular therapies for inflammatory DED and neuropathic corneal pain (NCP). The company's CEO, Dr. Gary S. Jacob, emphasized the importance of this patent in advancing their efforts to address unmet medical needs in ocular pain and inflammation treatment.

OKYO Pharma (NASDAQ: OKYO) announced that an interview with CEO Dr. Gary S. Jacob will air on Bloomberg TV's The RedChip Small Stocks, Big Money™ show on August 24, 2024, at 7 p.m. ET. The interview will provide a corporate update on OKYO's development of innovative therapies for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP).

OKYO's lead candidate, OK-101, a lipid-conjugated chemerin peptide, has shown promising results in a recent Phase 2 trial for DED, demonstrating improvements in symptoms and signs within 15 days with a favorable safety profile. The company is also targeting NCP, an ocular condition without FDA-approved treatments. OKYO has patent protection through 2039 and an experienced management team with a track record of successful clinical development and FDA approvals.

OKYO Pharma and SolarMax Technology are set to feature on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, August 24, at 7 p.m. ET. The show, available in an estimated 73 million U.S. homes, will air exclusive interviews with the CEOs of both companies.

OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharmaceutical company, is developing innovative therapies for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP). Their lead candidate, OK-101, showed promising results in a recent Phase 2 trial for DED, demonstrating improvements in symptoms and signs within 15 days.

SolarMax Technology (Nasdaq: SMXT), founded in 2008, has completed over 15,000 solar installations. The company is expanding its commercial solar development services in the U.S. market, with recent large-scale projects announced in Las Vegas and San Jose.

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, announced that its Executive Chairman, Gabriele Cerrone, has increased his stake in the company. Through Panetta Partners , an entity in which Cerrone has a beneficial interest, 50,000 ordinary shares were purchased on NASDAQ at $1.05 per share. This acquisition brings Cerrone's total shareholding to 9,721,570 shares, representing 28.73% of the company's issued share capital. OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP), targeting multi-billion-dollar markets.

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, has announced a significant insider purchase. Panetta Partners , an entity associated with Executive Chairman Gabriele Cerrone, acquired 35,000 ordinary shares of OKYO on NASDAQ at $1.00 per share. This transaction has increased Mr. Cerrone's total shareholding to 9,671,570 shares, representing 28.58% of the company's issued share capital.

OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. The company specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition without FDA-approved therapy.

OKYO's management will deliver a pre-recorded presentation available on-demand from 7:00 am EDT on the conference day. Interested parties can register for the conference and arrange virtual 1x1 meetings with OKYO's management through H.C. Wainwright representatives.

OKYO Pharma (NASDAQ: OKYO) has been granted a key European Patent for its OK-101 chemerin analogs and their method of use. This patent, titled 'Compositions Comprising Chemerin Analogs and Methods of Use', strengthens OKYO's intellectual property position in treating ocular inflammatory and pain conditions.

The company is developing innovative therapies for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), which currently lacks FDA-approved treatments. Dr. Gary S. Jacob, CEO of OKYO, emphasized the patent's importance in advancing novel therapies for ocular pain and inflammation. The company is exploring strategic partnerships to accelerate the development and commercialization of its pipeline candidates.

OKYO Pharma is set to begin a Phase 2 clinical trial of OK-101 for treating neuropathic corneal pain (NCP) in Q3 2024. This is the first instance of an FDA IND clearance for a drug targeting NCP, a significant unmet medical need. OK-101 has shown statistically significant pain relief in previous trials for dry eye disease and preclinical models of NCP. The 12-week, placebo-controlled trial will be led by Dr. Pedram Hamrah at Tufts Medical Center, involving 48 NCP patients. The study aims to measure pain improvement using a visual analogue scale (VAS).

CEO Dr. Gary S. Jacob emphasizes the potential of OK-101, highlighting its previous success in reducing pain in dry eye patients, some of whom suffer from NCP. The trial's design includes five study visits over 16 weeks, with pain improvement as the primary endpoint. Encouraging preclinical and clinical data support the trial's objectives. More details are available in the company's Form 6-K filing.

OKYO Pharma has announced promising new data from its Phase 2 trial of OK-101 for treating Dry Eye Disease (DED). The trial, involving 240 patients, showed a 68% improvement in the responder rate for those achieving both conjunctival staining and ocular pain endpoints. OK-101 demonstrated a strong tolerability profile, with favorable comfort scores. The analyses identified conjunctival staining and ocular pain as potential co-primary endpoints for future trials. CEO Gary S. Jacob emphasized these endpoints as important for ongoing development, targeting the underserved DED patient population with pain symptoms.